Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (6592)	1/27/2001 10:50:40 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

Hi CG, The bottom line is that for me the nature of this investment changed with the Provalis deal. All lights green to the revenue flow from the European market. Since I have confidence in Pennsaid's ability to grow sales well over time, I knew it was inevitable that I would see satisfactory growth in shareprice over the next couple of years and meet my low end goals. Having bought the majority of my shares around June 98 at an average 3.25 price - a $21 shareprice June 2002 breaks a 60% compounded annual return over 4 years and puts me nicely in line for my minimum 50% requirement over 5 years (over 7.5 times my original investment but at that pace I could have stayed in Bombardier). Time to relax. I'm in. And a premium for the risk looks good. Almost 3 weeks ago I posted on Stockhouse this shift in Dimethaid's nature and wondered out loud 'what else DMX can do' to up the ante. I may have hammered on the $50MM a bit - but what you cut out is the point and its a big one. Acqua believes Dimethaid will do considerably better than my numbers above. Europe doesn't cover that. So by this action, I know something else is on the way and its not small or incremental and Acqua likes it. In a nutshell, regardless of any short term dips, both the minimum needs and premium wants are looking good for this year of the snake. Mongo like stock.